Current treatments for endocrine disorders like Cushing's syndrome often have severe side effects that limit their utility. Similarly, polymyalgia rheumatica is commonly treated with steroid medicines that, while effective, also cause significant adverse effects, especially in elderly patients. These toxicities stem from elevated levels of active intracellular steroids in key tissues.

Sparrow Pharmaceuticals is developing therapies that target the source of intracellular steroids to mitigate their toxicities. Their lead candidate, clofutriben (SPI-62), is a selective HSD-1 inhibitor designed to reduce excess intracellular cortisol in patients with Cushing’s syndrome and autonomous cortisol secretion, potentially offering a safer and more tolerable treatment option. Sparrow is also developing SPI-47, a combination therapy of clofutriben and prednisolone, for polymyalgia rheumatica, aiming to deliver the therapeutic efficacy of glucocorticoids while minimizing their severe side effects. By inhibiting HSD-1, these therapies aim to lower active intracellular steroids, addressing the root cause of steroid-related toxicities.

Clofutriben (SPI-62): Oral, small molecule HSD-1 inhibitor to reduce excess intracellular cortisol.

SPI-47: Combination therapy of clofutriben and prednisolone for polymyalgia rheumatica.

Targets HSD-1: Selectively inhibits HSD-1 to lower active intracellular steroid levels.

Designed to mitigate steroid toxicities: Aims to reduce the adverse effects associated with steroid treatments.

Potential for improved safety and tolerability: Clofutriben may offer a stronger safety profile compared to existing Cushing's syndrome treatments.

The primary target audiences are patients with endocrine disorders such as Cushing’s syndrome and autonomous cortisol secretion, as well as elderly patients suffering from polymyalgia rheumatica.